Mechanisms of Mindfulness Intervention: Distress Tolerance Dose Manipulation
Launched by PEKING UNIVERSITY · Sep 20, 2023
Trial Information
Current as of June 26, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is looking at how different levels of a program called "distress tolerance intervention" can help people who are feeling emotionally distressed. The researchers want to see if giving more of this intervention makes mindfulness techniques—ways to focus the mind and calm feelings—more effective in reducing emotional distress. They will also explore if the ability to tolerate distress plays a role in how well mindfulness works for these individuals.
To participate in this study, you need to be between 18 and 65 years old and have a certain level of emotional distress, as measured by a specific scale. You should have been on any medication for at least four weeks without changes and must agree to take part voluntarily by signing a consent form. However, people who meditate frequently, have certain mental health conditions, or are at risk of suicide won't be eligible. If you join the study, you'll be helping researchers learn more about how mindfulness can be tailored to better support those dealing with emotional difficulties.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Age 18-65;
- • Subjects with scores greater than 21 on the Kessler Psychological Distress Scale.
- • If taking medication, haven't changed for at least 4 weeks before intervention onset and no change in medicine is expected;
- • Voluntary participation in this study and sign an informed consent form.
- Exclusion Criteria:
- • Subjects who have participated in mindfulness-based projects (especially MIED), and/or the current frequency of meditation practice is more than once a week;
- • Patients with schizophrenia or psychotic affective disorder, current organic mental disorder, substance abuse disorder, and generalized developmental disorder;
- • Subjects at risk of suicide.
About Peking University
Peking University is a prestigious institution located in Beijing, China, recognized for its commitment to advancing medical research and education. As a clinical trial sponsor, Peking University leverages its extensive academic resources and collaborative networks to drive innovative healthcare solutions. The university's focus on rigorous scientific methodologies and adherence to ethical standards ensures the integrity and reliability of its clinical research initiatives. By fostering interdisciplinary partnerships, Peking University aims to translate groundbreaking discoveries into tangible health benefits, contributing to the global advancement of medical science.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Beijing, Beijing, China
Patients applied
Trial Officials
Xinghua Liu
Principal Investigator
School of Psychological and Cognitive Sciences, Peking University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported